Compare iShares Core Growth Allocation ETF (AOR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Sana Biotechnology Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AOR | SANA | |
|---|---|---|
52-Week High | $70.12 | $5.92 |
52-Week Low | $62.26 | $2.68 |
Market Cap | — | $1.13B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% on the day. Technical indicators show a bullish trend with strong moving average signals, though the RSI suggests potential overbought conditions. The ETF maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low expense ratio of 0.20%.
The outlook for AOR is mixed; it offers diversified exposure and cost efficiency, but has underperformed the S&P 500 over the past decade. Key risks include market volatility and allocation strategy limitations. Analyst sentiment is generally positive for long-term core holdings.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
